NCT04562116View on ClinicalTrials.gov

A Study to Assess the Effects of Nemolizumab on Cytochrome P450 Substrates in Participants With Moderate-to-Severe Atopic Dermatitis

PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

December 8, 2021

Primary Completion Date

June 7, 2023

Study Completion Date

June 7, 2023

Conditions
Atopic Dermatitis
Interventions
DRUG

Nemolizumab

Nemolizumab 30 mg will be administered as SC injections.

DRUG

CYP 450 Substrates

CYP substrates (Caffeine, Warfarin Sodium, Midazolam, Omeprazole, and Metoprolol Tartrate) will administered orally at Week 0 (Day 1) and Week 10 as per the commercially available prescribing information.

Trial Locations (6)

1612

5952 Galderma Investigational Site, Sofia

27612

8030 Galderma Investigational Site, Raleigh

33009

9954 Galderma Investigational Site, Hallandale

33147

9923 Galderma Investigational Site, Miami

78759

8076 Galderma Investigational Site, Austin

91606

8894 Galderma Investigational Site, North Hollywood

Sponsors

Lead Sponsor

Galderma R&D
All Listed Sponsors
lead

Galderma R&D

INDUSTRY

NCT04562116 - A Study to Assess the Effects of Nemolizumab on Cytochrome P450 Substrates in Participants With Moderate-to-Severe Atopic Dermatitis | Biotech Hunter | Biotech Hunter